NASDAQ · EUCRU
Eucrates Biomedical Acquisition Corp.
Financial Services · Shell Companies
$10.02
Down-$0.07 (-0.69%)
Updated Aug 16, 2026, 12:51 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 47.26M
- P/E ratio
- 5.4
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 21.51K
- Avg. volume
- 581
Price performance
EUCRU price history
1M range · 0 trading sessions · Daily adjusted prices
EUCRU does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest EUCRU news
The latest Smart Investors Daily articles mentioning EUCRU.
Stock researchCompany · Overview
EUCRU research
Overview
Company profile and research snapshot.
Company profile
Eucrates Biomedical Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It focuses to identify and acquire a business in the biomedical or healthcare-related industries in North America and Europe. The company was incorporated in 2020 and is based in New York, New York.
Analyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
